Sanofi Pasteur reports increased immune responses with high dose vaccine

Pharmaceutical Company Product News

Sanofi Pasteur, which is the vaccines arm of Sanofi-Aventis, has found that a high-dose influenza vaccine produced increased immune responses in subjects aged 65 and over, compared to the standard vaccine.

The company is developing the candidate high-dose intramuscular influenza vaccine formation and reported results of its research at a conference in the US.

Around 4,000 people were involved in the phase III double-blind randomised study and all three influenza strains were investigated. A total of 2,575 received the high-dose and 1,262 were given the standard.

In the first group, "statistically significant" higher levels of serum hemagglutination inhibition titers - the unit used to measure immune response - against all three strains were found, Sanofi Pasteur said.

Study authors added that older adults can be more susceptible to influenza and less able to respond when they are affected.

According to the NHS, the influenza vaccine in the UK is able to provide between 70 and 80 per cent of protection against infection.

It contains one type of the influenza B virus and two types of influenza A.

One of the ongoing World Health Organisation projects is the Global Influenza Surveillance Network, which collects and identifies new strains to form the basis of recommendations for updated vaccines.

See all the latest jobs in Pharmaceutical
Return to news